14M115: Abstracts: SLE – Treatment (1651–1656)

Abstract Moderator(s)

• 

  Maureen McMahon, MD, MS

  Professor of Rheumatology
  UCLA David Geffen School of Medicine
  Los Angeles, CA, United States

  Disclosure(s): Astra Zeneca: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Aurinia: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Consultant (Ongoing); Glaxo Smith Kline: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Roberto Caricchio, MD

  University of Massachusetts Chan Medical School
  Worcester, MA, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose

Oral abstract session.

Presentations:

• 9:00 AM – 9:10 AM Eastern Time

  CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus
  

  Presenting Author: Georg Schett, MD – Friedrich Alexander University Erlangen-Nürnberg
• 9:10 AM – 9:15 AM Eastern Time

  Q&A
  
• 9:15 AM – 9:25 AM Eastern Time

  Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
  

  Presenting Author: Kenneth C. Kalunian, MD, FACR – UC San Diego
• 9:25 AM – 9:30 AM Eastern Time

  Q&A
  
• 9:30 AM – 9:40 AM Eastern Time

  Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies
  

  Presenting Author: Cristina Arriens, MD, MS – Oklahoma Medical Research Foundation
• 9:40 AM – 9:45 AM Eastern Time

  Q&A
  
• 9:45 AM – 9:55 AM Eastern Time

  Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
  

  Presenting Author: Jacquelyn Nestor, MD, PhD – Massachusetts General Hospital
• 9:55 AM – 10:00 AM Eastern Time

  Q&A
  
• 10:00 AM – 10:10 AM Eastern Time

  Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus
  

  Presenting Author: Eline Arends, MD, MSc – Leiden University Medical Center
• 10:10 AM – 10:15 AM Eastern Time

  Q&A
  
• 10:15 AM – 10:25 AM Eastern Time

  Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial
  

  Presenting Author: Anca Askanase, MD, MPH – Columbia University Medical Center
• 10:25 AM – 10:30 AM Eastern Time

  Q&A